HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kimio Yonesaka, Kazuhiko Nakagawa, Yasutaka Chiba et al.|Clinical Cancer Research|2021

Cited by 92